Starlix (nateglinide), a new oral tablet for type 2 diabetes
February 2001
Novartis is now marketing Starlix (nateglinide), a new oral tablet for type 2 diabetes.
Think of it as a shorter-acting Prandin (repaglinide).
Both meds are taken before meals to stimulate insulin release...but Starlix has a shorter duration.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote